1NM-PP1 treatment of mice infected with Toxoplasma gondii

Tatsuki Sugi, Kentaro Kato, Kyousuke Kobayashi, Hitomi Kurokawa, Hitoshi Takemae, Haiyan Gong, Frances C. Recuenco, Tatsuya Iwanaga, Taisuke Horimoto, Hiroomi Akashi

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Bumped kinase inhibitors (BKIs) target analog-sensitive kinases, which the genomes of mammals rarely encode. Previously, we demonstrated that a BKI effectively suppressed the in vitro replication of Toxoplasma gondii, the causative pathogen of toxoplasmosis, by targeting T. gondii calcium-dependent protein kinase 1 (TgCDPK1) (Eukaryotic Cell, 9: 667-670). Here, we examined whether the BKI 1NM-PP1 reduced parasite replication in vivo. A high dose of 1NM-PP1, by intraperitoneal injection, just before the parasite inoculation effectively reduced the parasite load in the brains, livers, and lungs of T. gondii-infected mice, however, a low dose of 1NMPP1 with oral administration didn't change the survival rates of infected mice.

Original languageEnglish
Pages (from-to)1377-1379
Number of pages3
JournalJournal of Veterinary Medical Science
Issue number10
Publication statusPublished - 2011 Oct
Externally publishedYes


  • 1NM-PP1
  • Bumped kinase inhibitor
  • Drug
  • Protein kinase
  • Toxoplasma gondii

ASJC Scopus subject areas

  • veterinary(all)


Dive into the research topics of '1NM-PP1 treatment of mice infected with Toxoplasma gondii'. Together they form a unique fingerprint.

Cite this